Full Press Release Details
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44thannual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.
44th Annual J.P. Morgan Healthcare Conference
| Date: | Monday, January 12, 2026 |
| Time: | 4:30pm PST |
| Format: | Presentation |
| Webcast: | Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializingDefenCath®(taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, includingMINOCIN®(minocycline) for Injection,REZZAYO®(rezafungin for injection), VABOMERE®(meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA®(delafloxacin), andKIMYRSA®(oritavancin), as well asTOPROL-XL®(metoprolol succinate).
CorMedix has ongoing clinical studies forDefenCathin Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to developDefenCathas a catheter lock solution for use in other patient populations.REZZAYOis currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit:www.cormedix.comorwww.melinta.com.